<DOC>
	<DOCNO>NCT01924078</DOCNO>
	<brief_summary>The present study determine adverse effect clinical efficacy AI combine Capecitabine metronomic chemotherapy postmenopausal breast cancer patient Estrogen receptor and/or Progestrogen receptor positive .</brief_summary>
	<brief_title>Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor Postmenopausal Hormone Receptor Positive Breast Cancer</brief_title>
	<detailed_description>Capecitabine ( Xeloda ® ) currently biologically active oral fluoropyrimidine drug , widely use first-line second-line rescue therapy advance breast cancer , third-generation aromatase inhibitor ( AI ) prefer adjuvant endocrine therapy Postmenopausal hormone-sensitive breast cancer . Study show AI combine metronomic chemotherapy could improve objective response clinical benefit neoadjuvant therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>1 . Hormone receptor positive ; 2. previously untreated patient receive hormonal therapy , initial endocrine treatment failure first line endocrine treatment relapse metastasis failure ; 3. patient receive hormonal therapy must histologically confirm invasive ductal carcinoma , surgery , must satisfy one following : ( 1 ) elderly ( ≥70 year ) , severe heart systemic complication , belong high risk general anesthesia , ( 2 ) conserving breast , large tumor ( ≥3cm ) suitable breastconserving surgery . 4. patient metastatic breast cancer must evaluable lesion 5. normal laboratory value : 6. informed consent ( ethical approval document No . :11121051 ) ; 7. life expectancy least 3 month ; 8 . Postmenopausal premenopausal bilateral oophorectomy . 1. radiotherapy local treatment measurable lesion start study receive within 3 month 2. organ transplant ( except autologous allogeneic bone marrow transplantation ) ; 3. evidence central nerve system metastases history mental illness uncontrol ; 4. unable swallow tablet , malabsorption patient , patient poor upper gastrointestinal integrity ; 5. unwilling unable comply study protocol unable meet follow ; 6. patient researcher consider suitable participate .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>metronomic chemotherapy</keyword>
	<keyword>aromatase inhibitor</keyword>
</DOC>